Did our AI summary help? Miltenyi Biotec, the German cell and gene therapy (CGT) specialist that quietly powers much of the world’s CAR‑T manufacturing ecosystem, is preparing a major push into ...
Hyderabad attracts over 75 greenfield GCCs in 2025, surpassing Karnataka's 40+ establishments. The city becomes India's second-largest product engineering GCC hub, focusing on core SaaS and life ...
Add Yahoo as a preferred source to see more of our stories on Google. HSP-CAR30 CAR-T therapy offers lasting remission in refractory lymphoma, showing 100% response in early trials. (CREDIT: ...
DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...
Seventeen patients with R/R MCL received a single dose of LV20.19 CAR T cells at 2.5 × 10 6 cells/kg (phase I = three patients; phase II = 14 patients). The best overall response rate (ORR) was 100% ...
Mumbai, India-based Sun Pharma has acquired Checkpoint Therapeutics for $355 million in an all-cash transaction. The deal is expected to close in the second quarter of 2025. Through this acquisition, ...
Advancing a cell therapy from preclinical research to clinical trials is no small feat. Many companies grapple with challenges such as process scalability, regulatory compliance, and ensuring product ...
Miltenyi Biotec launched India's first Cell and Gene Therapy Center in Hyderabad. The Miltenyi Innovation and Technology Center aims to drive disease treatment innovations through integrated expertise ...
Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...
MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies ...
SAN DIEGO – Fresh, never-frozen autologous CAR T cells targeting both CD19 and CD20 antigens on lymphomas demonstrated encouraging efficacy in an early readout from the DALY II USA clinical trial ...
Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma. Tecelra’s approval comes with several firsts. It’s the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results